2seventy bio Inc Ordinary Shares TSVT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if TSVT is a good fit for your portfolio.
News
-
2seventy Bio Sells Gene Editing Therapy To Novo Nordisk for Up To $40 Million
-
2seventy bio Announces Sale of Hemophilia A Candidate and MegaTAL In Vivo Gene Editing Technology to Novo Nordisk for up to $40 million
-
2seventy bio to Participate in Upcoming Investor Conferences
-
2seventy bio Reports First Quarter Financial Results and Recent Operational Progress
-
2seventy bio to Report First Quarter 2024 Financial Results on May 8, 2024
-
Bristol Myers, 2seventy Get FDA OK for Earlier Abecma Use in Multiple Myeloma
-
2seventy Bio Shares Soar Premarket as FDA Panel Backs Abecma
-
2seventy Bio Shares Fall on Concerns About FDA Panel's Meeting on Abecma Gene Therapy
Trading Information
- Previous Close Price
- $4.57
- Day Range
- $4.53–4.83
- 52-Week Range
- $1.54–8.95
- Bid/Ask
- $4.43 / $4.95
- Market Cap
- $246.23 Mil
- Volume/Avg
- 337,211 / 509,605
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 3.46
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- 0.03%
Company Profile
2seventy bio Inc is a cell and gene therapy company focused on the research, development, and commercialization of transformative treatments for cancer. The company operates in a single segment, focusing on researching, developing and commercializing potentially transformative treatments for cancer.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 425
- Website
- https://www.2seventybio.com
Comparables
Valuation
|
Metric
|
TSVT
|
EQRX
|
ACLX
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 1.19 | 0.97 | 6.91 |
Price/Sales | 3.46 | — | 24.24 |
Price/Cash Flow | — | — | 475.08 |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
TSVT
|
EQRX
|
ACLX
|
|---|---|---|---|
Quick Ratio | 3.20 | 18.43 | 5.32 |
Current Ratio | 3.52 | 18.78 | 5.46 |
Interest Coverage | — | — | −22.10 |
Quick Ratio
TSVT
EQRX
ACLX
Profitability
|
Metric
|
TSVT
|
EQRX
|
ACLX
|
|---|---|---|---|
Return on Assets (Normalized) | −26.49% | −15.72% | −1.99% |
Return on Equity (Normalized) | −54.52% | −16.71% | −3.75% |
Return on Invested Capital (Normalized) | −31.87% | −21.31% | −7.24% |
Return on Assets
TSVT
EQRX
ACLX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk A/S ADR
NVO
| Yjgcclvny | Zblj | $565.6 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Tzjmlrwc | Kqnslq | $127.8 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Jmwcvzgm | Djhpqs | $118.7 Bil | |||
| Moderna Inc
MRNA
| Xbpwsbbm | Yfww | $46.8 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Lkzbxyvpc | Yzbkvy | $29.7 Bil | |||
| argenx SE ADR
ARGX
| Lwfhsxpm | Dyng | $29.3 Bil | |||
| BioNTech SE ADR
BNTX
| Rzkymsbll | Tchtt | $20.7 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Dbsclql | Jjqdyh | $16.1 Bil | |||
| United Therapeutics Corp
UTHR
| Vhzfglstj | Bbdlk | $15.0 Bil | |||
| Incyte Corp
INCY
| Vqzhfvxdn | Jqdrwkg | $13.5 Bil |